TABLE 2.
Treatments administered to patients in the BAC arm
| Category and regimen | Overall (N = 49) [n (%)] |
|---|---|
| Systemic chemotherapy | 24 (49.0) |
| Carboplatin/paclitaxel | 3 (6.1) |
| Dacarbazine | 1 (2.0) |
| Temozolomide | 20 (40.8) |
| Chemoembolization | 11 (22.4) |
| Carmustinea | 3 (6.1) |
| Cisplatin | 2 (4.1) |
| Doxorubicin/cisplatin/mitomycin | 3 (6.1) |
| Doxorubicin | 1 (2.0) |
| Doxorubicin/cisplatin | 2 (4.1) |
| Radioembolization (with Yttrium Y-90 SirSpheres) | 3 (6.1) |
| Combination systemic chemotherapy/embolizationb | 1 (2.0) |
| Surgery | 1 (2.0) |
| Supportive care | 9 (18.4) |
BAC Best alternative care
Treatments administered after randomization and before disease progression
a
Patient 012–354 received two cycles of inter-arterial carmustine followed by one cycle of intra-arterial paclitaxel
b
Patient 03–259 received seven cycles of inter-arterial gemcitabine combined with intravenous paclitaxel